US DoD Naval Medical Research Center Clinical Update
Filed with ASX · · 2 pages · English
Key Points • Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed. • IND submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support Two human phase II clinical trials. • One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea caused by ETEC and schedul
Earlier from Immuron
- IMM124E Demonstrates Antiviral T-Cell Immunity
- Reinstatement to Official Quotation
- Immuron planned Acquisition of R&D Vaccine Company
- Preliminary Final Report
- Voluntary Suspension
Later from Immuron
- US DoD Travelan Clinical Update
- Immuron Receives European Patent on Drug to Treat Diarrhea
- Response to ASX Query
- Half Yearly Report and Accounts
- Immuron Q3 Global Sales up 216% YoY
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron